Abiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysis.

Melek Karakurt EryilmazMustafa Karaağaç

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)

Abiraterone is an oral inhibitor of cytochrome P450 (17alpha)-hydroxylase/17,20 lyase (CYP17) complex critical to androgen production. Abiraterone in combination with prednisone is currently FDA approved for use in men with metastatic castration-resistant prostate cancer, both in the pre- and post-chemotherapy settings. This article discusses the treatment with abiraterone in a patient with metastatic castration-resistant prostate cancer on hemodialysis.

Keyphrases

squamous cell carcinoma
small cell lung cancer
case report
peritoneal dialysis
end stage renal disease
chronic kidney disease
locally advanced
radiation therapy
chemotherapy induced